Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

81. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. Full Text available with Trip Pro

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. Muscle-related statin intolerance is reported by 5% to 20% of patients.To identify patients with muscle symptoms confirmed by statin rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe and evolocumab.Two-stage randomized clinical trial including 511 adult patients with uncontrolled low-density lipoprotein cholesterol (...) (LDL-C) levels and history of intolerance to 2 or more statins enrolled in 2013 and 2014 globally. Phase A used a 24-week crossover procedure with atorvastatin or placebo to identify patients having symptoms only with atorvastatin but not placebo. In phase B, after a 2-week washout, patients were randomized to ezetimibe or evolocumab for 24 weeks.Phase A: atorvastatin (20 mg) vs placebo. Phase B: randomization 2:1 to subcutaneous evolocumab (420 mg monthly) or oral ezetimibe (10 mg daily).Coprimary

2016 JAMA Controlled trial quality: predicted high

82. More HOPE for Prevention with Statins. (Abstract)

, Veterans Affairs Medical Center, Memphis, TN (W.C.C.); and the Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (D.C.G.). eng Editorial Comment 2016 04 02 United States N Engl J Med 0255562 0028-4793 0 Antihypertensive Agents 0 Benzimidazoles 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors 0 Tetrazoles 0J48LPH2TH Hydrochlorothiazide 83MVU38M7Q Rosuvastatin Calcium AIM IM N Engl J Med. 2016 May 26;374(21):2032-43 27039945 N Engl J Med. 2016 May 26;374(21):2009-20 (...) 27041480 N Engl J Med. 2016 May 26;374(21):2021-31 27040132 N Engl J Med. 2016 Sep 22;375(12 ):1192-3 27653576 N Engl J Med. ;375(12 ):1194 28102987 Antihypertensive Agents administration & dosage Benzimidazoles administration & dosage Cardiovascular Diseases prevention & control Female Humans Hydrochlorothiazide administration & dosage Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage Hypercholesterolemia drug therapy Hypertension drug therapy Male Rosuvastatin Calcium

2016 NEJM

83. Statin-Associated Autoimmune Myopathy. (Abstract)

Statin-Associated Autoimmune Myopathy. 26886523 2016 03 01 2016 02 18 1533-4406 374 7 2016 Feb 18 The New England journal of medicine N. Engl. J. Med. Statin-Associated Autoimmune Myopathy. 664-9 10.1056/NEJMra1515161 Mammen Andrew L AL eng Journal Article Review United States N Engl J Med 0255562 0028-4793 0 Glucocorticoids 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors VB0R961HZT Prednisone AIM IM Algorithms Autoimmune Diseases chemically induced drug therapy Glucocorticoids therapeutic use (...) Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects Muscle, Skeletal pathology Muscular Diseases chemically induced drug therapy immunology pathology Prednisone therapeutic use 2016 2 18 6 0 2016 2 18 6 0 2016 3 2 6 0 ppublish 26886523 10.1056/NEJMra1515161

2016 NEJM

84. Statin Choice Electronic Decision Aid

Statin Choice Electronic Decision Aid Statin Choice Decision Aid - Site Statin Choice Decision Aid Welcome to the Statin Choice Decision Aid. This tool will help you and your doctor discuss how you might want to reduce your risk for heart attacks. Caution: This application is for use exclusively during the clinical encounter with your clinician (Updated May, 2018) (Updated February 6, 2015) LEGAL CONDITIONS AND TERMS OF USE APPLICABLE TO ALL USERS OF THIS SITE. ANY USE OF THIS SITE CONSTITUTES (...) YOUR AGREEMENT TO THESE TERMS AND CONDITIONS OF USE. © 1998-2019 Mayo Foundation for Medical Education and Research. All rights reserved. Generating Report... Cancel Statin Choice Decision Aid To: CC: Subject:

2016 Washington Health Care Authority

85. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

enhanced gene expression. Many of the same transcription factors involved in the upregulation of CYP450 enzymes (eg, constitutive androstane receptor and pregnane X receptor) also enhance the expression of P-gp. Although reports vary, atorvastatin, lovastatin, pitavastatin, and simvastatin have been implicated as both P-gp substrates and inhibitors. Common P-gp substrates, inducers, and inhibitors that affect statin metabolism are given in . , , Table 3. Common P-gp Substrates, Inhibitors, and Inducers (...) Associated With the CYP450 Enzymes Affecting Statin Metabolism , , Enzyme Statin Substrates Inhibitors Inducers CYP2C9 Fluvastatin, rosuvastatin (also CYP2C19, minor) Amiodarone, capecitabine, etravirine, fluconazole, fluvoxamine, fluvastatin,ketoconazole, metronidazole, miconazole, oxandrolone, sulfamethoxazole/trimethoprim, voriconazole, zafirlukast Carbamazepine, phenobarbital, phenytoinrifampin CYP3A4 Atorvastatin, lovastatin, simvastatin Amiodarone,amlodipine, aprepitant, atorvastatin, bicalutamide

2016 American Heart Association

86. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication

, race, cholesterol levels, systolic blood pressure level, antihypertension treatment, presence of diabetes, and smoking status as risk factors. Preventive Medication Statins are a class of lipid-lowering medications that function by inhibiting the enzyme 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Statins reduce levels of total cholesterol and LDL-C and, to a lesser extent, triglycerides. The most directly applicable body of evidence for patients without a history of CVD demonstrates benefits (...) of every 3 deaths among adults. Statins are a class of lipid-lowering medications that function by inhibiting the enzyme 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, which is involved in the rate-limiting step in the production of cholesterol. Statins reduce levels of total cholesterol and LDL-C and, to a lesser extent, triglycerides, and probably have anti-inflammatory and plaque stabilization effects as well. Potential Benefits of Statin Use The USPSTF found adequate evidence that use of low

2016 U.S. Preventive Services Task Force

87. Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease (Abstract)

Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease Statins are extensively used to treat dyslipidemia, but, because of their low tolerability profile, they are discontinued in a significant proportion of patients. Ezetimibe and nutraceuticals have been introduced as alternative therapies and have proved to be effective and well tolerated. A single-blind, single-center, randomized, prospective (...) the therapeutic goal. No patients experienced important undesirable effects. In conclusion, nutraceuticals alone or in combination with ezetimibe are well tolerated and improve the lipid profile in statin-intolerant patients with coronary heart disease. Further studies are needed to assess long-term effects of nutraceuticals on mortality.Copyright © 2015 Elsevier Inc. All rights reserved.

2015 EvidenceUpdates Controlled trial quality: uncertain

88. A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk Full Text available with Trip Pro

A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, significantly reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This phase 3 study evaluated the efficacy and safety of evolocumab plus atorvastatin in Japanese patients with hyperlipidemia or mixed dyslipidemia and high cardiovascular risk. Patients were randomized to atorvastatin 5 (...) between treatment groups. Efficacy and safety for Q2W or QM evolocumab dosing were similar. In conclusion, in high-risk Japanese patients receiving stable statin therapy, evolocumab markedly reduced LDL-C and was well tolerated.Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

2015 EvidenceUpdates Controlled trial quality: uncertain

89. Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy. Full Text available with Trip Pro

AR NIAMS NIH HHS United States Letter Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural United States N Engl J Med 0255562 0028-4793 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors 0 Immunoglobulins, Intravenous AIM IM Autoimmune Diseases chemically induced drug therapy Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects Immunoglobulins, Intravenous therapeutic use Middle Aged Muscular Diseases chemically induced drug therapy 2015 10 22 6 0 2015 10 22 6 (...) Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy. 26488714 2015 10 27 2018 11 13 1533-4406 373 17 2015 Oct 22 The New England journal of medicine N. Engl. J. Med. Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy. 1680-2 10.1056/NEJMc1506163 Mammen Andrew L AL National Institutes of Health, Bethesda, MD andrew.mammen@nih.gov. Tiniakou Eleni E eng T32 AR048522 AR NIAMS NIH HHS United States ZIA AR041203-01 NULL Intramural NIH HHS United States T32-AR-048522

2015 NEJM

90. Ezetimibe plus a Statin after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444734 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1476-7 10.1056/NEJMc1509363 Cannon Christopher P CP Blazing Michael A MA Braunwald Eugene E eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV (...) Cholesterol, LDL blood Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Male Simvastatin therapeutic use 2015 10 8 6 0 2015 10 9 6 0 2015 10 9 6 1 ppublish 26444734 10.1056/NEJMc1509363 10.1056/NEJMc1509363#SA8

2015 NEJM

91. Ezetimibe plus a Statin after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444735 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1473 10.1056/NEJMc1509363 Silbernagel Günther G Baumgartner Iris I März Winfried W eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV (...) Simvastatin AIM IM N Engl J Med. 2015 Jun 18;372(25):2387-97 26039521 N Engl J Med. 2015 Oct 8;373(15):1476-7 26444734 Acute Coronary Syndrome drug therapy Anticholesteremic Agents therapeutic use Azetidines therapeutic use Cholesterol, LDL blood Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Male Simvastatin therapeutic use 2015 10 8 6 0 2015 10 9 6 0 2015 10 9 6 1 ppublish 26444735 10.1056/NEJMc1509363 10.1056/NEJMc1509363#SA1

2015 NEJM

92. Ezetimibe plus a Statin after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444736 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1473-4 10.1056/NEJMc1509363 Couture Philippe P Durand Madeleine M Laskine Mikhael M eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV (...) Simvastatin AIM IM N Engl J Med. 2015 Jun 18;372(25):2387-97 26039521 N Engl J Med. 2015 Oct 8;373(15):1476-7 26444734 Acute Coronary Syndrome drug therapy Anticholesteremic Agents therapeutic use Azetidines therapeutic use Cholesterol, LDL blood Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Male Simvastatin therapeutic use 2015 10 8 6 0 2015 10 9 6 0 2015 10 9 6 1 ppublish 26444736 10.1056/NEJMc1509363 10.1056/NEJMc1509363#SA2

2015 NEJM

93. Ezetimibe plus a Statin after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444737 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1474 10.1056/NEJMc1509363 Egom Emmanuel E EE eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV Simvastatin AIM IM N Engl J Med. 2015 Jun (...) 18;372(25):2387-97 26039521 N Engl J Med. 2015 Oct 8;373(15):1476-7 26444734 Acute Coronary Syndrome drug therapy Anticholesteremic Agents therapeutic use Azetidines therapeutic use Cholesterol, LDL blood Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Male Simvastatin therapeutic use 2015 10 8 6 0 2015 10 9 6 0 2015 10 9 6 1 ppublish 26444737 10.1056/NEJMc1509363 10.1056/NEJMc1509363#SA3

2015 NEJM

94. Ezetimibe plus a Statin after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444738 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1474-5 10.1056/NEJMc1509363 Patti Giuseppe G Cavallari Ilaria I eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV Simvastatin AIM IM N Engl J (...) Med. 2015 Jun 18;372(25):2387-97 26039521 N Engl J Med. 2015 Oct 8;373(15):1476-7 26444734 Acute Coronary Syndrome drug therapy Anticholesteremic Agents therapeutic use Azetidines therapeutic use Cholesterol, LDL blood Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Male Simvastatin therapeutic use 2015 10 8 6 0 2015 10 9 6 0 2015 10 9 6 1 ppublish 26444738 10.1056/NEJMc1509363 10.1056/NEJMc1509363#SA4

2015 NEJM

95. Ezetimibe plus a Statin after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444739 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1475 10.1056/NEJMc1509363 Nunes José P L JP eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV Simvastatin AIM IM N Engl J Med. 2015 Jun 18;372 (...) (25):2387-97 26039521 N Engl J Med. 2015 Oct 8;373(15):1476-7 26444734 Acute Coronary Syndrome drug therapy Anticholesteremic Agents therapeutic use Azetidines therapeutic use Cholesterol, LDL blood Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Male Simvastatin therapeutic use 2015 10 8 6 0 2015 10 9 6 0 2015 10 9 6 1 ppublish 26444739 10.1056/NEJMc1509363 10.1056/NEJMc1509363#SA5

2015 NEJM

96. Ezetimibe plus a Statin after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444740 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1475-6 10.1056/NEJMc1509363 Richard Thibault T Lelubre Christophe C Vanhaeverbeek Michel M eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV (...) Simvastatin AIM IM N Engl J Med. 2015 Jun 18;372(25):2387-97 26039521 N Engl J Med. 2015 Oct 8;373(15):1476-7 26444734 Acute Coronary Syndrome drug therapy Anticholesteremic Agents therapeutic use Azetidines therapeutic use Cholesterol, LDL blood Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Male Simvastatin therapeutic use 2015 10 8 6 0 2015 10 9 6 0 2015 10 9 6 1 ppublish 26444740 10.1056/NEJMc1509363 10.1056/NEJMc1509363#SA6

2015 NEJM

97. Ezetimibe plus a Statin after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444741 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1476 10.1056/NEJMc1509363 Singh Jagdeep S JS Struthers Allan D AD Lang Chim C CC eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV Simvastatin (...) AIM IM N Engl J Med. 2015 Jun 18;372(25):2387-97 26039521 N Engl J Med. 2015 Oct 8;373(15):1476-7 26444734 Acute Coronary Syndrome drug therapy Anticholesteremic Agents therapeutic use Azetidines therapeutic use Cholesterol, LDL blood Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Male Simvastatin therapeutic use 2015 10 8 6 0 2015 10 9 6 0 2015 10 9 6 1 ppublish 26444741 10.1056/NEJMc1509363 10.1056/NEJMc1509363#SA7

2015 NEJM

98. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines Full Text available with Trip Pro

Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines In the general population, the majority of cardiovascular events occur in people at the low to moderate end of population risk distribution. The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol recommends consideration of statin therapy for adults (...) with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥7.5% based on traditional risk factors. Whether use of nontraditional risk markers can improve risk assessment in those below this threshold for statin therapy is unclear.Using data from the Multi-Ethnic Study of Atherosclerosis (MESA), a population sample free of clinical CVD at baseline, we calibrated the Pooled Cohort Equations (cPCE). ASCVD was defined as myocardial infarction, coronary heart disease death, or fatal or nonfatal

2015 EvidenceUpdates

99. Do statins increase the risk of developing diabetes?

Do statins increase the risk of developing diabetes? Do statins increase the risk of developing diabetes? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do statins increase the risk of developing diabetes? View/ Open Date 2015-04 Contributor Format Metadata Abstract Q: Do statins increase the risk of developing (...) diabetes? A: Yes. Statin therapy produces a small increase in the incidence of diabetes: one additional case per 255 patients taking statins over 4 years (strength of recommendation [SOR]: A, meta-analysis). Intensive statin therapy, compared with moderate therapy, produces an additional 2 cases of diabetes per 1000 patient years (SOR: B, meta-analysis with significant heterogeneity among trials). URI Citation Journal of Family Practice, 64(4) 2015: 245-246. Rights OpenAccess. This work is licensed

2015 Clinical Inquiries

100. Do statins increase the risk of developing diabetes?

Do statins increase the risk of developing diabetes? Do statins increase the risk of developing diabetes? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do statins increase the risk of developing diabetes? View/ Open Date 2015-04 Contributor Format Metadata Abstract Q: Do statins increase the risk of developing (...) diabetes? A: Yes. Statin therapy produces a small increase in the incidence of diabetes: one additional case per 255 patients taking statins over 4 years (strength of recommendation [SOR]: A, meta-analysis). Intensive statin therapy, compared with moderate therapy, produces an additional 2 cases of diabetes per 1000 patient years (SOR: B, meta-analysis with significant heterogeneity among trials). URI Citation Journal of Family Practice, 64(4) 2015: 245-246. Rights OpenAccess. This work is licensed

2015 Clinical Inquiries